Cologuard Plus is only noninvasive test to be evaluated head-to-head against an independent fecal immunochemical test, which it significantly outperformed
20,000-participant BLUE-C study included 98 colorectal cancers and reflects racial and ethnic diversity of U.S.
Company will host conference call and webcast at 8:00 a.m. ET on March 14 to discuss study resultsContinue reading